Biologic Therapies, Psoriasis, and COVID-19: Our Experience at the Psoriasis Unit of the University of Naples Federico II.
作者信息
Camela Elisa, Fabbrocini Gabriella, Cinelli Eleonora, Lauro Wanda, Megna Matteo
机构信息
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy,
出版信息
Dermatology. 2021;237(1):13-14. doi: 10.1159/000513575. Epub 2020 Dec 9.
Abstract
摘要
相似文献
1
Biologic Therapies, Psoriasis, and COVID-19: Our Experience at the Psoriasis Unit of the University of Naples Federico II.生物疗法、银屑病与新型冠状病毒肺炎：那不勒斯费德里科二世大学银屑病治疗中心的经验
Dermatology. 2021;237(1):13-14. doi: 10.1159/000513575. Epub 2020 Dec 9.
2
Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.银屑病的生物疗法：从临床角度进行的依从性与疗效分析。
Australas J Dermatol. 2016 May;57(2):137-40. doi: 10.1111/ajd.12294. Epub 2015 Mar 5.
3
Efficacies of biological therapies at week 12 in patients with plaque psoriasis in real-world academic clinical practice: a Canadian multicentre retrospective study.现实世界学术临床实践中斑块状银屑病患者接受生物疗法12周时的疗效：一项加拿大多中心回顾性研究。
Br J Dermatol. 2017 Jul;177(1):297-298. doi: 10.1111/bjd.15069. Epub 2017 Jun 11.
4
Medication adherence among patients with psoriasis on traditional systemic and biologics treatment.接受传统全身治疗和生物制剂治疗的银屑病患者的药物依从性。
Br J Dermatol. 2018 Jan;178(1):e46-e48. doi: 10.1111/bjd.15856. Epub 2017 Dec 12.
5
Efficacy of biologic therapies in psoriasis vulgaris.寻常型银屑病的生物制剂治疗疗效。
Dermatol Ther. 2019 Jul;32(4):e12936. doi: 10.1111/dth.12936. Epub 2019 Apr 25.
6
Switching biologics in severe pediatric psoriasis: a retrospective analysis.重度儿童银屑病生物制剂的转换：一项回顾性分析
Int J Dermatol. 2017 Dec;56(12):1461-1464. doi: 10.1111/ijd.13752. Epub 2017 Sep 27.
7
Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.儿童银屑病的生物治疗：一项回顾性观察研究，评估生物药物在儿童银屑病日常治疗中的生存情况。
J Eur Acad Dermatol Venereol. 2019 Oct;33(10):1984-1992. doi: 10.1111/jdv.15579. Epub 2019 Apr 15.
8
Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study.西班牙临床实践中中度至重度银屑病常规全身治疗和生物治疗的药物留存率：撒哈拉研究的前瞻性结果
J Dermatolog Treat. 2020 Jun;31(4):344-351. doi: 10.1080/09546634.2019.1597244. Epub 2019 Jun 20.
9
Satisfaction and Awareness of Systemic Psoriasis Treatments: A National Survey Comparing Biologic and Nonbiologic Users.系统性银屑病治疗的满意度与认知度：一项比较生物制剂和非生物制剂使用者的全国性调查
J Cutan Med Surg. 2019 Mar/Apr;23(2):148-156. doi: 10.1177/1203475418808764. Epub 2019 Feb 25.
10
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.美国皮肤病学会-银屑病基金会联合指南：生物制剂治疗银屑病的管理与治疗。
J Am Acad Dermatol. 2019 Apr;80(4):1029-1072. doi: 10.1016/j.jaad.2018.11.057. Epub 2019 Feb 13.
引用本文的文献
1
Biologics and Biosimilars in Psoriasis.银屑病中的生物制剂和生物类似药
Indian J Dermatol. 2023 May-Jun;68(3):282-295. doi: 10.4103/ijd.ijd_421_23.
2
Inflammation Causes Exacerbation of COVID-19: How about Skin Inflammation?炎症导致 COVID-19 恶化：皮肤炎症呢？
Int J Mol Sci. 2022 Oct 14;23(20):12260. doi: 10.3390/ijms232012260.
3
Letter to the editor regarding the article "Oguz Topal I, Kara Polat A, Zindancı İ, et al. Adherence to systemic therapy in patients with psoriasis during the COVID-19 pandemic: A multicenter study. J Cosmet Dermatol. 2021;10.1111/jocd.14610.".致编辑的信，关于文章《奥古兹·托帕尔一世、卡拉·波拉特 A、津丹奇 İ 等人。COVID-19 大流行期间银屑病患者对系统治疗的依从性：一项多中心研究。《美容皮肤病学杂志》。2021 年；10.1111/jocd.14610》。
J Cosmet Dermatol. 2022 Mar;21(3):880-882. doi: 10.1111/jocd.14781. Epub 2022 Jan 27.
4
Biologics for Psoriasis During the COVID-19 Pandemic.新冠疫情期间用于治疗银屑病的生物制剂
Front Med (Lausanne). 2021 Dec 6;8:759568. doi: 10.3389/fmed.2021.759568. eCollection 2021.
5
Letter to the editor regarding article "Yalici-Armagan B, Tabak GH, Dogan-Gunaydin S, Gulseren D, Akdogan N, Atakan N. Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course. J Cosmet Dermatol. 2021;00:1-5".致编辑的信：关于文章“Yalici-Armagan B, Tabak GH, Dogan-Gunaydin S, Gulseren D, Akdogan N, Atakan N. 新冠疫情早期生物制剂治疗银屑病：一项关于患者对治疗及疾病进程态度的研究。《美容皮肤科杂志》。2021年；00:1 - 5”
J Cosmet Dermatol. 2021 Dec;20(12):4073-4075. doi: 10.1111/jocd.14550. Epub 2021 Oct 28.
6
Influence of SARS-CoV-2 Virus Infection on the Course of Psoriasis during Treatment with Biological Drugs.新型冠状病毒感染对生物制剂治疗银屑病过程中疾病的影响。
Medicina (Kaunas). 2021 Aug 27;57(9):881. doi: 10.3390/medicina57090881.
7
Clinical Dermatology and COVID-19 Pandemic: Narrative Review.临床皮肤病学与新冠疫情：叙述性综述
Indian J Dermatol. 2021 May-Jun;66(3):246-255. doi: 10.4103/ijd.ijd_463_21.
8
Biologics for Psoriasis during the COVID-19 Pandemic.新冠疫情期间用于治疗银屑病的生物制剂
J Clin Med. 2021 Mar 30;10(7):1390. doi: 10.3390/jcm10071390.
本文引用的文献
1
COVID-19 and psoriasis: biologic treatment and challenges.COVID-19 与银屑病：生物治疗及挑战
J Dermatolog Treat. 2022 Mar;33(2):699-703. doi: 10.1080/09546634.2020.1789051. Epub 2020 Jul 6.
2
Biologic agents in psoriasis: our experience during coronavirus infection.银屑病中的生物制剂：我们在冠状病毒感染期间的经验。
Int J Dermatol. 2020 Aug;59(8):e266-e267. doi: 10.1111/ijd.15002. Epub 2020 Jun 9.
3
Psoriasis, biologic therapy, and the pandemic of the 21st century.银屑病、生物疗法与21世纪的大流行
Drugs Context. 2020 May 14;9. doi: 10.7573/dic.2020-4-10. eCollection 2020.
4
COVID-19 and biologics for psoriasis: A high-epidemic area experience-Bergamo, Lombardy, Italy.新型冠状病毒肺炎与银屑病生物制剂：高流行地区的经验——意大利伦巴第大区贝加莫市
J Am Acad Dermatol. 2020 Jul;83(1):292-294. doi: 10.1016/j.jaad.2020.04.165. Epub 2020 May 6.
5
COVID-19 and psoriasis: Should we fear for patients treated with biologics?COVID-19 与银屑病：接受生物制剂治疗的患者是否需要担心？
Dermatol Ther. 2020 Jul;33(4):e13434. doi: 10.1111/dth.13434. Epub 2020 May 5.
Zotero 插件